AbbVie Inc.
United States · Biopharma, Biotechnology, Healthcare
Venture capital subsidiary of Abbvie
Key facts
- Headquarters
- United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (ABBV)
- Website
- abbviebiotechventures.com
- Company page
Recent activity at AbbVie Inc.
- : AbbVie to Acquire Aliada Therapeutics, Appoints Roopal Thakkar as Executive Vice President and Chief Scientific Officer
- : AbbVie to acquire Karuna Therapeutics for schizophrenia progress
- : AbbVie completed an $8.75 billion note offering to partially fund its acquisition of Apogee Therapeutics.
- : SEC 8-K (8.01): On August 18, 2026, AbbVie Inc. completed its previously announced underwritten public offering of Senior Notes. This offering included various series of notes, with maturities ranging from 2027 to 2031, featuring interest rates from 0.750% to 2.625%. The completion of this public offering indicates the company's strategy to raise capital through debt financing. This transaction may enhance AbbVie's liquidity and support its operational and investment activities.
- : Mayo LGFA and AbbVie announce three-year title sponsorship for adult championship.
- : AbbVie to acquire Apogee Therapeutics for $10.9B
- : AbbVie to acquire Cerevel Therapeutics for $8.7B
- : SEC 8-K (1.01): On March 4, 2026, AbbVie Inc. entered into a material definitive agreement concerning the issuance of senior notes. This agreement includes various series of notes, including 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031. The notes are registered under the ticker symbols ABBV27, ABBV28, ABBV28B, ABBV29, and ABBV31 on the New York Stock Exchange. The issuance of these notes is significant for AbbVie as it enhances its capital structure and provides funding for future operations and research initiatives. The detailed financial terms, including interest rates and maturity dates, reflect AbbVie's strategic approach to managing its debt portfolio.
- : SEC 8-K (2.02): On February 4, 2026, AbbVie Inc. issued a press release announcing its financial results for the fourth quarter 2025. The report details the company's revenue, net income, and earnings per share, showcasing growth compared to the previous year's quarter. The announcement is aimed at informing investors of the company’s operational performance and financial health, which is critical in guiding investment decisions. This event is significant as it aligns with the end of the financial quarter and provides insight into AbbVie's performance amidst market dynamics.
- : AbbVie to acquire Revolution Medicines soon
AbbVie Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $8.8B |
| May 2016 | Venture | $3.8B |
Leadership
- Frederick Waddell, Director
- Glenn Tilton, Director
- Edward Rapp, Director
- Brett Hart, Director
- Edward Liddy, Director
- William Burnside, Director
- Roxanne Austin, Director
- Robert Alpern, Director
- Richard Gonzalez, Executive Officer, Director
- Thomas Hurwich, Executive Officer
- Azita Saleki-Gerhardt, Executive Officer
- Timothy Richmond, Executive Officer
Verified email and direct lines for AbbVie Inc.’s decision-makers are on Fundz. See plans
Companies similar to AbbVie Inc.
- Milestone Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Reneo Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- ISOThrive · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About AbbVie Inc.: questions and answers
What does AbbVie Inc. do?
Venture capital subsidiary of Abbvie
Where is AbbVie Inc. headquartered?
AbbVie Inc. is headquartered in United States.
Has AbbVie Inc. raised funding?
Yes. Fundz has recorded 2 funding events for AbbVie Inc.. The most recent, $8.8B, was in Aug 2026.
What is the latest news on AbbVie Inc.?
On Sep 01, 2026, AbbVie to Acquire Aliada Therapeutics, Appoints Roopal Thakkar as Executive Vice President and Chief Scientific Officer
Is AbbVie Inc. a public company?
Yes. AbbVie Inc. is publicly traded under the ticker ABBV.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy